|제목||BioCore and KDePRI enter into an MOU to advance radio-isotope detection technology (2019. 4.18)|
BioCore and KDePRI enter into an MOU to advance radio-isotope detection technology
On this date, BioCore, Korea's leading Contract Research Organization (CRO) for personalized medicine, entered into a Memorandum of Understanding (MOU) with the Korean Drug Development Platform using Radio-Isotope (KDePRI), located at Korean Institute of Radiological and Medical Sciences (KIRAMS; Nowon-gu, Seoul). The agreement was signed by the Director of New Drug Development Division, 오수연 of BioCore and the Director of KDePRI, 심재훈. The agreement defines a mutually beneficial collaboration where BioCore will provide specialized sample processing and GLP oversight for clinical development studies of new drug molecules requiring radio-isotopes In return KDePRI will provide access to its advanced radio-isotope detection technology and expert staff who are focused on accelerating drug development for Korean and Global Pharmaceutical Partners.
KDePri is a government-affiliated institution that specializes in radiolabeled ADME, bioimaging and radiopharmaceutical production and analysis under GLP and GMP regulatory conditions. It is houses state-of-the-art equipment run by experts in a purpose-built, 7-story facility. KDePRI facilitates the application of radioisotopes to new drug development. It welcomes any and all researchers and pharmaceutical companies to utilizes any of its many services.
Contact firstname.lastname@example.org for more information.
BioCore is Korea's largest and oldest CRO, with a long history of providing high quality GLP clinical services for Bioequivalency and Phase 1 and 2 clinical development. It is an integrated CRO that uses an array of bioanalyical tools coupled with patented DNA assays to address the rapidly growing need for personalized medicine. BioCore is currently listed on the KONEX stock market.
Contact email@example.com at www.bio-core.com for more information.